

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number
WO 2005/093429 A2

- (51) International Patent Classification⁷: G01N 33/68
- (21) International Application Number:
PCT/IB2005/000795
- (22) International Filing Date: 23 March 2005 (23.03.2005)
- (25) Filing Language: Italian
- (26) Publication Language: English
- (30) Priority Data:
MI2004A000598 26 March 2004 (26.03.2004) IT
- (71) Applicant (for all designated States except US): BRINI, Marisa [IT/IT]; Via Crescini 6/ter, I-35126 Padova (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

- (71) Applicants and
- (72) Inventors: RIZZUTO, Rosario [IT/IT]; Via Crescini 6/ter, I-35126 Padova (IT). POZZAN, Tullio [IT/IT]; Via Brenta Bassa 73, I-30031 Dolvo (IT). PINTON, Paolo [IT/IT]; Via L. Da Vinci 12, I-35132 Padova (IT). GIORGI, Carlotta [IT/IT]; Via Roma 113, I-46037 Roncoferraro (IT).
- (74) Agents: COPPO, Alessandro et al.; Ing. Barzanò & Zanardo Milano S.p.A., Via Borgonuovo 10, I-20121 Milan (IT).

Published:
— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR THE DETECTION OF INTRACELLULAR PARAMETERS WITH LUMINESCENT PROTEIN PROBES FOR THE SCREENING OF MOLECULES CAPABLE OF ALTERING SAID PARAMETERS



(57) Abstract: The invention relates to a method for the detection of intracellular parameters by means of luminescent recombinant protein probes for the screening of molecules capable of altering said target intracellular parameters.

WO 2005/093429 A2

5

METHOD FOR THE DETECTION OF INTRACELLULAR PARAMETERS WITH
LUMINESCENT PROTEIN PROBES FOR THE SCREENING OF MOLECULES
CAPABLE OF ALTERING SAID PARAMETERS

10 The present invention relates to a method for the
detection of intracellular parameters by means of lumi-
nescent recombinant protein probes, for the screening of
molecules capable of altering said parameters.

 In particular, the present invention relates to a
15 method for detecting intracellular parameters and/or ac-
tivities by means of luminescent protein probes for the
screening of molecules of pharmacological and/or cosmetic
and/or environmental interest capable of altering said
parameters and/or activities.

20 It is known that cells forming the organism have a
continuous exchange of information, both with other cells
and with the extracellular environment.

 Communication between the cells is guaranteed by
their capacity to receive and send signals of a chemical
25 nature interacting with specific receptors present on

their plasmatic membrane. In most cases, the activation of these receptors causes the generation of intracellular messengers, called second messengers, which convey the information brought by the extra-cellular messenger (or
5 first messenger) into the cell. With respect to the extreme variety of extra-cellular mediators, the number of known second messengers is surprisingly limited: the calcium ion (Ca^{2+}), inositol 1,4,5 triphosphate (IP_3), diacylglycerol (DAG), nucleotides of adenosine and cyclic
10 nucleotides (cAMP and cGMP).

These second messengers in turn activate a series of intracellular performers, called cellular response effectors, which, through a variation in the intracellular parameters, are capable of triggering a series of events
15 until a definitive cellular response is obtained.

Cellular parameters are those values, such as concentration, activation state, cellular localization, which enable us to understand and consequently describe the activity exerted by each single element present inside the cell (ions, proteins, nucleotides, signal molecules).
20

Variation of said cellular parameters refers to a modification in the normal basic indexes (variation in concentration, translocation to the plasmatic membrane, activation or inactivation), in response to certain stim-
25

uli (physiological or pharmacological) deriving from the extra-cellular environment.

Environmental, chemical, physical or genetic factors can create pathological conditions which cause alterations of the transduction pathways of the cellular signal.

In order to understand the functioning of a drug, it is necessary to avail of methods which allow the accurate monitoring of the various intracellular parameters on which the drugs and their variations must act.

At present, there are techniques for detecting only some of the cellular mediators involved in the transduction pathways of the signal and in most cases, these techniques are not efficient and/or easily applicable to massive screening methods of thousands of molecules, a strongly felt requirement, on the other hand, on the part of pharmaceutical, chemical or cosmetic industries.

The most widely-studied cellular mediator was and still is the calcium ion (Ca^{2+}). It has been seen that a wide variety of stimuli, ranging from growth factors to neuro-transmitters, are transmitted inside the cell by means of variations in the cytosol concentration of Ca^{2+} ($[\text{Ca}^{2+}]_c$).

Ca^{2+} is an ubiquitous ion normally present in all cellular compartments, which, through variations in its

concentration, is capable of regulating numerous cellular functions.

The development of the first techniques for measuring the concentration of Ca^{2+} goes back to the sixties' and represented the start of a detailed understanding of the mechanisms that regulate $[\text{Ca}^{2+}]_c$ and its role in controlling the numerous biological functions.

The first $[\text{Ca}^{2+}]_c$ measurements were effected by micro-injecting into huge cells of *Balanus*, a Ca^{2+} -sensitive photo-protein, aequorin (Ridgway and Ashley, 1967); in subsequent years, metallochromic indicators and specific micro-electrodes were often used. In both cases, the techniques were limited by the necessity of micro-injecting the indicator or inserting an electrode into the cell and consequently by the possibility of using few large dimensional cellular types.

In the nineties', the use of fluorescent Ca^{2+} indicators such as, for example, quin2 and fura-2, capable of passing through the plasmatic membrane and remaining entrapped at a cytoplasmatic level (Tsien et al., 1982, Grynkiewicz et al., 1985), allowed the cellular homeostasis of Ca^{2+} to be studied in many cellular types and to demonstrate the ubiquitous role of this ion. The facility of use of fluorescent indicators, however, is opposed by the incapacity of being selectively accumulated in the

various cellular organelles.

The above techniques, however, cannot be easily applied to pharmacological screening studies and are in any case limited to the measuring of Ca^{2+} alone.

5 The arrival of molecular biological techniques contributed, in the nineties', to the development of new methods for monitoring the Ca^{2+} ion based on the construction of protein probes which are introduced inside the cells by means of transfection techniques. There are
10 currently two categories of recombinant probes for Ca^{2+} .

 The first group exploits the fluorescent characteristics of molecules deriving from the fluorescent protein GFP (Green Fluorescent Protein, Zhang et al., 2002). These probes are difficult to use for pharmacological
15 screening as they require extremely costly procedures in terms of time and the ratio between the fluorescent signal obtained under standby and activation conditions is not sufficiently wide to allow use for automated methods.

 The second category of probes, is based on the use
20 of bioluminescent proteins capable of binding the Ca^{2+} and consequently emitting a luminous radiation, which can be measured and correlated to the concentration of the Ca^{2+} itself, among which aequorin.

 Aequorin, extracted and purified in 1962 from a species of luminescent medusa, *Aequorea Victoria* (Shimomura
25

et al., 1962), is a protein of about 22 kDa consisting of an apoprotein and a hydrophobic prosthetic group, celenterazine, bound to the apoprotein by means of a covalent link of the peroxide type.

5 The Ca^{2+} link with aequorin at a level of 3 specific high affinity sites of the "EF-hand" type, induces a conformational modification of the protein itself and consequent breakage of the covalent link and emission of photons and release of the oxidized coenzyme.

10 It is possible to measure the variation in the $[\text{Ca}^{2+}]$ thanks to the existence of a relation between the logarithm of the emission rate of photons (L), expressed as a fraction with respect to the maximum luminescence rate, i.e. under saturation conditions (L/L_{max}) and the
15 logarithm of $[\text{Ca}^{2+}]$. These values, obtained through *in vitro* measurements, under known conditions of pH, ion strength $[\text{Mg}^{2+}]$ and temperature, allow a sigmoid-shaped calibration curve to be constructed, on the basis of which, within the range of Ca^{2+} concentrations from 0.1-
20 10 μM (and over 100 μM using mutated aequorin (Montero et al., 1995), it is possible to correlate, at each moment, the fraction of aequorin consumed with the $[\text{Ca}^{2+}]$ value at which the photo-protein is exposed. The conversion of the luminous signal obtained from the cells, is based on
25 this relation, in values of $[\text{Ca}^{2+}]$.

Aequorin, as bioluminescent marker, has advantages with respect to fluorescent indicators as it can be easily directed into the various cellular compartments by the use of appropriate regulating elements or signal peptides, representing a reliable instrument for measuring the variations in the concentration of Ca^{2+} (Rizzuto et al., 1992). In particular, this publication describes the technique for directing and measuring the Ca^{2+} concentrations at a mitochondria level.

10 Various recombinant probes of aequorin were subsequently developed, directed towards other cellular compartments such as, for example, nucleus (Brini et al., 1993; Brini et al., 1994), endoplasmatic reticulum (Montero et al., 1995), Golgi apparatus (Pinton et al., 15 1998), mitochondria inter-membrane space (Rizzuto et al., 1998), sarcoplasmatic reticulum (Brini et al., 1997), sub-membrane region (Marsault et al., 1997) which made it possible to determine the variations in the concentration of Ca^{2+} in the various cellular districts following various kinds of stimulation.

Another advantage of luminescence is that, with respect to fluorescence, it does not require an excitation light thus avoiding self-fluorescence and photobleaching phenomena. Furthermore, aequorin is not toxic, it does not form links with other cations and does not interfere

25

with the intracellular Ca^{2+} concentration.

The authors previously studied the use of a Ca^{2+} sensitive recombinant photo-protein, such as aequorin, expressed in mammal cells as an alternative method for
5 measuring the concentration of the Ca^{2+} ion (Rizzuto et al., 1993; Rizzuto et al., 1994; Brini et al., 1994b; Rizzuto et al., 1995; Brini et al., 1995; De Giorgi et al., 1996; Rutter et al., 1996; Brini et al., 1999; Robert et al., 2000; Porcelli et al., 2001; Chiesa et al.,
10 2001).

The use of aequorin has a series of technique advantages described hereunder:

- a) optimum signal/noise relation as mammal cells do not have endogenous luminescent protein;
- 15 b) it integrates the data of a transfected population, thus avoiding errors depending on cellular variability;
- c) the aequorin probe can be stably expressed alone in a cellular line (thus obtaining a "permanent" and repeatable screening system), or stably co-expressed with specific
20 receptors of interest (thus simplifying the functional analysis of the specific signaling systems);
- d) extremely simple detection system, as it is sufficient to collect the whole light emission spectrum emitted, which is suitable for the miniaturization of the sample
25 to be analyzed and automation, as the luminous signal is

strong (the light emission increases logarithmically with the variation in the Ca^{2+} concentration).

It is interesting to observe, however, that although variations in the calcium ion can be easily detected, 5 they are only involved in a few of the numerous signal transduction pathways of pharmaceutical interest. As already specified, there are, however, many other transduction pathways which involve other cellular elements (cellular effectors, enzymes, ion channels, second messen- 10 gers) which are difficult to detect directly, but which are extremely important for identifying molecules of potential pharmacological or toxicological interest.

In view of what is indicated above, there is evidently the necessity for availing of effective, sensitive 15 and rapid methods for the detection of intracellular parameters and/or activities, for the screening of molecules suitable for generating specific alterations in said parameters and/or activities.

The authors of the present invention have now developed 20 new methods capable of indirectly detecting variations in the intracellular parameters, retracing said variations to corresponding variation of the concentration of the Ca^{2+} ion which can be easily detected. In particular, bioluminescent detections systems have been 25 set up, based on the use of the aequorin photo-protein,

capable of emitting luminous signals in response to variations in the concentration of Ca^{2+} , which reflect the variation in other intracellular parameters or enzymatic activities in response to certain physiological and/or pharmacological stimulations.

The conversion of intracellular parameters and activities into a variation of the calcium concentration enables both the second messenger generation, such as cAMP, for example, as well as the activation and/or translocation of performer proteins, such as, for example, the kinase proteins (regulating proteins such as PKC) or the proteins of the shc family (protein adaptors such as p46shc, p52shc or p66shc) to be followed.

Among performer proteins of interest, the authors of the present invention examined, for illustrative purposes, the protein kinase C (PKC) and the protein p66shc. As PKC and p66shc, following activation, translocate from the cytoplasm to the plasmatic membrane where the concentration of the calcium ion is greater with respect to the concentration in the cytoplasm, the authors created a PKC/aequorin and p66shc/aequorin chimerical proteins particularly sensitive to the different Ca^{2+} concentration. In this way, the translocation to the membrane and consequent activation of the PKC and p66shc were correlated to an indirect parameter such as the different Ca^{2+} concen-

tration in the two cellular areas (cytoplasm and sub-membrane area).

The authors show that the luminous signal of PKC-aequorin and p66shc-aequorin at the level of the membrane is (due to the non-linearity of the luminescence function with respect to the $[Ca^{2+}]$) at least 50-100 times more intense with respect to that of a PKC-aequorin and p66shc-aequorin probe at a non-activated cytoplasmatic level. The luminescent signal of chimerical proteins considered is much more intense after induction of translocation with a known activator, as is shown in figures 1-6 relating to the experiments effected with a prototype of these chimerical proteins.

The method identified by the authors allows the translocation/activation of the proteins to be simply, economically and efficiently quantified, as the light emission increases proportionally with the translocation degree, and a screening of compounds, active on said proteins, to be effected.

In parallel, the authors of the present invention applied the same innovative system for converting the concentration values of second messengers into Ca^{2+} concentration values, i.e. transforming a signal which is difficult to quantify into a signal that can be easily detected, again using aequorin as detection system.

Among second messengers, the authors of the present invention examined cAMP. In this case, chimerical receptors were developed, in which the intracellular portion of the original receptor was substituted, i.e. the portion capable of activating the cellular response through the production of cAMP, with the intracellular portion of a receptor (coupled with Gq proteins) capable of inducing a variation in the concentration of Ca^{2+} inside the cell. In this way, once the chimerical receptor has been stimulated, it will induce increases in the concentration of calcium rather than of cAMP.

A condensed aequorin was used as detection probe, at a signal frequency that directs it towards mitochondria (mt-AEQ) (Rizzuto et al., 1992), as a result of its greater sensitivity due to the fact that the mitochondria "amplify" the increases in concentration of cytosol calcium. As it can be inferred from figures 7 and 8, the luminescent signal of the mt-AEQ probe is comparable in cells treated with a stimulation normally associated with increases in the concentration of calcium (histamine and ATP) or in cells treated with a stimulation associated with increases in the concentration of cAMP (isoproterenol or nociceptine).

Another application of this type of luminescent probes based on aequorin found by the authors of the pre-

sent invention is represented by the possibility of analyzing the catalytic activity of cellular effectors (such as PKC) which act on the ionic channels of calcium and identifying drugs which interfere with said catalytic activity. The calcium channels are localized on the membranes of important cellular compartments, such as, for example, the plasmatic membrane, the membrane of the endoplasmatic reticulum or the internal mitochondrial membrane. These are involved in the fine regulation of the intracellular homeostasis of calcium and alterations in their function are associated with pathological conditions.

For this purpose, the authors used an appropriate aequorin probe (variable in relation to the cellular compartment on which the channel of interest is localized) and a cellular line expressing (endogenously or following engineering) the calcium channel positively or negatively regulated by the cellular effector, in the specific case by PKC negatively.

In the system set up by the authors, it is possible to identify the substances which act by inhibiting the catalytic activity of PKC through the detection of an increase in the luminescent signal of aequorin indicating the flow of calcium through the channel which cannot be closed by the kinase enzymatic action.

The various applications of the luminescent probes produced by the authors of the present invention, allow the differentiated screenings to be effected, of the molecules to be tested and as they can be easily automated, they can be used both for HTS (high throughput screening) analyses and for MTS (medium throughput screening) or LTS (low throughput screening) measurements.

The object of the present invention therefore relates to a screening method according to the enclosed claims.

In a preferred embodiment of the present invention, a screening method is provided, for molecules capable of generating the alteration of a target intracellular parameter, said alteration being converted into a proportional variation of the intracellular concentration of the Ca^{2+} ion detected by means of a Ca^{2+} -sensitive recombinant protein probe, comprising the following phases:

- a) construction of an expression vector containing the sequence encoding said probe, said sequence being characterized in that it comprises sequences encoding a Ca^{2+} -sensitive photo-protein, preferably aequorin, and at least one cellular effector or a signal sequence, condensed together;
- b) transfection of at least one cellular line of a mam-

mal with said vector containing the Ca^{2+} -sensitive recombinant protein probe;

- c) activation of aequorin by the addition of a prosthetic group, preferably celenterazine, to the cellular line expressing said recombinant protein probe;
- d) administration of the molecule to be tested to the cellular line expressing said recombinant protein probe;
- e) detection of the emission of photons on the part of the Ca^{2+} -sensitive photo-protein, preferably aequorin, expressed in the cellular line.

For greater clarity, the term " Ca^{2+} -sensitive photo-protein" refers to any amino acidic sequence capable of emitting photons, following the bond with calcium ions; aequorin and obelin proteins are particularly important from an applicative point of view.

"Performer or effector proteins refers to regulating proteins, proteins which link membrane receptors, proteins which link membrane channels, proteins which link membrane lipids.

"Regulating protein" refers to any amino acidic sequence capable of modifying the activity and/or structure of other cellular components, following its interaction with other signal molecules.

"Proteins that link membrane receptors" refer to those amino acidic sequences capable of interacting with

receptors situated at the level of cellular membranes. Among these, it is possible to distinguish adaptors which allow the interaction between the activated receptor and a third protein, and modulators which directly interfere
5 with the activity of the receptor.

The term "proteins that link membrane channels" indicate those amino acidic sequences capable of interacting with channels situated at the level of cellular membranes.

10 Furthermore, the term "proteins that link membrane lipids" are identified as those amino acidic sequences capable of interacting with lipids situated at the level of cellular membranes.

Finally, the term cellular compartment refers to any
15 region inside the cell preferably delimited by cellular membranes such as: cytoplasm, area below the plasmatic membrane, nucleus, mitochondria, endo-sarcoplasmatic reticulum, Golgi apparatus, vesicles, lyso-endosomes.

The present invention is described hereunder for illustrative but non-limiting purposes, according to its preferred embodiments, with particular reference to the
20 figures of the enclosed drawings, in which:

figure 1 shows a graph which illustrates the measuring of the translocation entity (cps) of the probe with
25 the isoform PKC β -aequorin in the presence or in the ab-

sence of PMA stimulation and the difference with respect to the aequorin cytosolic cyt-AEQ probe;

figure 2 shows the graph which illustrates the measuring of the translocation entity (cps) of the probe with the isoform PKC δ -aequorin in the presence or in the absence of PMA stimulation and the difference with respect to the aequorin cytosolic cyt-AEQ probe;

fig. 3 shows the graph which illustrates the measuring of the translocation entity (cps) of the probe with the PKC ϵ -aequorin isoform in the presence or in the absence of PMA stimulation and the difference with respect to the aequorin cytosolic cyt-AEQ probe;

figure 4 shows the graph which illustrates the measuring of the translocation entity (cps) of the probe with the PKC ζ -aequorin isoform in the presence or in the absence of PMA stimulation and the difference with respect to the aequorin cytosolic cyt-AEQ probe;

figure 5 shows a graph which illustrates the measuring of the translocation entity (cps) of the PKC β -AEQ probe under hyperglycaemia conditions in the presence or absence of a drug;

figure 6 shows the graph which illustrates the measuring of the translocation entity (cps) of the p66shc-AEQ probe in the presence or in the absence of EGF stimulation and the difference with respect to the aequorin cy-

tosolic cyt-AEQ probe;

figure 7 shows the graph which illustrates the measuring of the entity (cps) of the cAMP concentration increase in the presence of the beta adrenergetic receptor and isoprotenol or of the beta/alpha adrenergetic chimerical receptor and isoprotenol or histamine;

figure 8 shows the graph which illustrates the measuring of the entity (cps) of the cAMP concentration increase in the presence of the wild-type ORL1 receptor for nociceptine and of nociceptine or of the adrenergetic ORL1/alpha chimeric receptor and of ATP or nociceptine.

EXAMPLE 1: Analysis of the translocation to the plasmatic membrane of a cellular effector of interest, the kinase protein C (PKC).

15 MATERIALS AND METHODS

Construction of a PKC-aequorin chimeric probe

In order to validate our procedure, various types of a series of PKC-aequorin chimeric probes were designed, each containing a different PKC isoform:

- 20 1) PKC beta-aequorin (beta PKC: ref. M13975)
- 2) PKC delta-aequorin (delta PKC: ref. M18330);
- 3) PKC epsilon-aequorin (epsilon PKC: ref. AF028009);
- 4) PKC zeta-aequorin (zeta PKC: ref. M18332);
- 5) PKC gamma-aequorin;
- 25 6) PKC alpha-aequorin (alpha PKC: ref. M13973);

- 7) PKC lambda-aequorin;
- 8) PKC theta-aequorin (theta PKC: ref. L07032);
- 9) PKC eta-aequorin.

In particular, the nucleotide sequence of aequorin
 5 used for the construction of PKC-aequorin probes is the
 following:

ATG AAG CTT TAT GAT GTT CCT GAT TAT GCT AGC CTC AAA
 CTT ACA TCA GAC TTC GAC AAC CCA AGA TGG ATT GGA CGA
 CAC AAG CAT ATG TTC AAT TTC CTT GAT GTC AAC CAC AAT
 10 GGA AAA ATC TCT CTT GAC GAG ATG GTC TAC AAG GCA TCT
 GAT ATT GTC ATC AAT AAC CTT GGA GCA ACA CCT GAG CAA
 GCC AAA CGA CAC AAA GAT GCT GTA GAA GCC TTC TTC GGA
 GGA GCT GGA ATG AAA TAT GGT GTG GAA ACT GAT TGG CCT
 GCA TAT ATT GAA GGA TGG AAA AAA TTG GCT ACT GAT GAA
 15 TTG GAG AAA TAC GCC AAA AAC GAA CCA ACG CTC ATC CGT
 ATA TGG GGT GAT GCT TTG TTT GAT ATC GTT GAC AAA GAT
 CAA AAT GGA GCC ATT ACA CTG GAT GAA TGG AAA GCA TAC
 ACC AAA GCT GCT GGT ATC ATC CAA TCA TCA GAA GAT TGC
 GAG GAA ACA TTC AGA GTG TGC GAT ATT GAT GAA AGT GGA
 20 CAA CTC GAT GTT GAT GAG ATG ACA AGA CAA CAT TTA GGA
 TTT TGG TAC ACC ATG GAT CCT GCT TGC GAA AAG CTC TAC
 GGT GGA GCT GTC CCC TAA.

In the specific example, the results presented re-
 late to the use of the PKC beta-aequorin (PCK β -AEQ), PKC
 25 delta-aequorin (PCK δ -AEQ), PKC epsilon-aequorin (PCK ϵ -

AEQ), PKC zeta-aequorin (PCK ζ -AEQ) probes.

These probes were obtained by inserting, in a eukaryotic expression vector (pcDNA3; 5.4 kb), the sequence encoding the various PKC isoforms condensed in
5 frame with the sequence encoding aequorin described above.

The localization of the chimeric probe was determined by signal peptides contained inside the native sequence of the protein whose intracellular path is to be
10 followed, in this specific case PKC. The addition of the cDNA of aequorin to the C-terminal of the sequence encoding PKC does not alter either the orientation or the physiological behaviour of the protein being examined.

At this point, transfection is effected in different
15 cellular lines of the chimeric probe obtained, such as HeLa, Cos 7 or Hek 293 cells.

Engineering of the cellular line

In the example illustrated, it was not necessary for the cellular line used to express any other element to
20 activate the cellular response. It is possible, however, depending on study requirements, to induce the cells to express a specific receptor for the molecule/drug to be tested in order to ensure an effective linkage degree, thus simplifying the functional analysis of the transduc-
25 tion systems.

Cellular transfection

The cells cultivated on cellular culture flasks (75 cm²) were transfected with a vector containing the chimeric probe produced, using the most suitable transfection techniques for the cellular line in question. As the HeLa stabilized cellular line was used as experimental model, the calcium phosphate technique was adopted as transfection method which guarantees a high percentage of positive cells for this cellular line.

10 Collection of cells expressing the chimeric probe

36 hours after transfection, the cells contained in the flask were detached from the bottom by trypsinization. The cellular suspension was then transferred to a Falcon tube (15 to 50 ml) and subjected to centrifugation at 1200 rpm at 20°C and finally the cellular precipitate was re-suspended in KRB (Krebs-Ringer modified buffer: 125 mM NaCl, 5 mM KCl, 1 mM Na₃PO₄, 1 mM MgSO₄, 5.5 mM glucose, 20 mM HEPES, pH 7.4, 37°C).

20 Reconstitution of the aequorin photo-protein to active form

The prosthetic group celentherazine was added to the suspension of cells expressing the PKC-aequorin probe at a final concentration of 5 μM.

Planting on multi-well plates

25 50 μl of suspension containing transfected cells

(corresponding to about 100,000 cells) were planted in each well of the plate. The cells were left to adhere for a time varying from 1 to 2 hours keeping them in the dark, due to the photo-instability of celenterazine.

5 Detection of the response

At the end of the incubation time, the various molecules to be tested were added to each well and the plate with the treated cells was then put in direct contact with a photo-multiplier which measures the emission of
10 photons on the part of aequorin.

RESULTS

This simple test can be used for testing compounds capable of modulating the translocation of PKC in live cells.

15 Figures 1-4 show the graphs which indicates the measuring of the translocation to cps of PKC beta, delta, epsilon and delta, according to the method described above.

The examples shown were carried out on two parallel
20 batches of cells:

a) HeLa cells expressing the PKC-aequorin (PKC-AEQ) probe (dark lines).

These cells were in turn subdivided into:

- HeLa PKC-aequorin cells treated with PMA (1 μ M,
25 SIGMA) to imitate the action of a drug (thick dark

line);

- control HeLa PKC-aequorin cells non treated with PMA
(thin dark line);

b) HeLa cells expressing the cytosol aequorin probe
5 (cyt-AEQ) (not condensed to any protein) (light
lines).

These cells were in turn subdivided into:

- HeLa cells with cytosol aequorin treated with PMA to
imitate the action of a drug (thick light line);

10 - control HeLa cells with cytosol aequorin non treated
with PMA (thin light line).

As can be observed from the trend of the graphs
shown in figure 1-4, in the absence of external calcium,
the emission of photons (expressed as cps: counts per
15 second) has a very low intensity (lower than 100 cps),
under all the conditions examined. Under such conditions,
in fact, the concentration of calcium in the cytoplasm,
where the cyt-AEQ probes (both in the absence and in the
presence of PMA forbol ester) and PKC-AEQ probes (in the
20 absence of PMA) are located, and below the plasmatic mem-
brane, i.e. where the PKC-AEQ probe translocates follow-
ing treatment with PMA, is very low (0.1 μM).

The addition of external calcium induces a signifi-
cant flow of this ion through the channels situated on
25 the plasmatic membrane with a consequent increase in the

concentration of calcium in the region below the plas-
matic membrane. Under these conditions, an enormous in-
crease in the emission of photons is registered (>
100,000 cps) only in the cells expressing the PKC-AEQ
5 probe, treated with PMA, indicating the complete translo-
cation of the kinase.

In all the other groups of cells, there is no sig-
nificant variation in the emission of photons (lower than
10,000 cps) on the part of aequorin.

10 From the graph, it is evident that all the cps val-
ues higher than those observed in the absence of the
maximal activator (PMA) will indicate a complete translo-
cation of the kinase. With this system, it is therefore
possible not only to identify the molecules capable of
15 inducing a translocation, but also to evaluate the amount
of activation or inhibition exerted by the molecule
tested, on the basis of a ratio between the cps value ob-
tained and the maximum cps value registered under condi-
tions of maximum stimulation of the cellular line.

20 The translocation efficiency can be determined by
expressing it on the basis of a range between the cps
value obtained under control conditions (0%) (without
PMA) and that obtained following maximal translocation
(100%) (after treatment with PMA), which can be described
25 as follows:

- GOOD activator for values ranging from 70% to 100% with respect to the maximal activator;
- MEDIUM activator for values ranging from 40% to 70% with respect to the maximal activator;
- 5 - POOR activator for values ranging from 10% to 40% with respect to the maximal activator;
- NON-activator for values below 10% with respect to the maximal activator.

This result clearly shows the validity of the system
10 proposed for measuring the translocation of proteins from the cytosol compartment to the plasmatic membrane in response to external stimulations.

EXAMPLE 2: Analysis of the translocation to the plasmatic membrane of beta PKC under hyperglycaemia conditions.

15 MATERIALS AND METHODS

Construction of the chimeric PKC-aequorin probe

A beta-aequorin PKC probe, already described in example 1, was used, with which HUVEC endothelial cells were transfected.

20 Engineering of the cellular line

In the example provided, it was not necessary for the cellular line used to previously express any other element to start the cellular response. It is possible, however, depending on the study requirements, to induce
25 the cells to express a specific receptor for the mole-

cule/drug to be tested in order to assure a sufficient linkage degree, thus simplifying the functional analysis of the transduction systems.

Cellular transfection

5 The cells cultivated on cellular culture flasks (75 cm²) were transfected with a vector containing the chimeric probe produced, using the most suitable transfection techniques for the cellular line in question. Endothelial cells of stabilized umbilical cord veins, called
10 HUVEC, were used as the experimental model, which were transfected with the PKC beta-aequorin probe, using lipofectamine which guarantees a high percentage of positive cells for this cellular line.

Collection of the cells expressing the chimeric probe

15 36 hours after transfection, the cells contained in the flask were detached from the bottom by trypsinization. The cellular suspension was then transferred to a Falcon tube (of 15 or 50 ml) and subjected to centrifugation at 1,200 rpm and at 20°C, and finally the cellular
20 precipitate was re-suspended in KRB (Krebs-Ringer modified buffer: 125 mM NaCl, 5 mM KCl, 1 mM Na₃PO₄, 1 mM MgSO₄, 5.5 mM glucose, 20 mM HEPES, ph 7.4, 37°C).

Reconstitution of the aequorin photo-protein to active form

25 The prosthetic group celentherazine at a final con-

centration of 5 μM was added to the cell suspension expressing the PKC beta-aequorin probe.

Planting on multi-well plates

50 μl of suspension containing transfected cells (corresponding to about 100,000 cells) were planted in each well of the plate. The cells were left to adhere for a time varying from 1 to 2 hours, keeping them in the dark, due to the photo-instability of celentherazine.

Detection of the response

10 At the end of the incubation time, the various molecules to be tested were added to each well and the plate with the treated cells was then put in direct contact with a photo-multiplier which measures the emission of photons on the part of aequorin.

15 RESULTS

This simple test can therefore be used for testing compounds capable of modulating the PKC translocation into the live cells.

20 Figure 5 shows a graph which indicates the measuring of the PKC beta translocation, according to the method described above.

The example provided was carried out on three parallel batches of cells:

25 a) HUVEC cells expressing the PKC beta-aequorin (PKC β -AEQ) probe, maintained under control conditions (absence

of glucose) (dotted line).

b) HUVEC cells expressing the PKC beta-aequorin (PKC β -AEQ) probe, maintained under hyperglycaemia conditions (10 mM of glucose) (dark, thick line).

5 c) HUVEC cells expressing the PKC beta-aequorin (PKC β -AEQ) probe, maintained under hyperglycaemia conditions (10 mM of glucose) treated with a well-known anti-diabetic agent, metformin (20 μ M) (dark, thin line).

As can be seen from the trend of the graph shown in
10 figure 5, the emission of photons (expressed as cps: counts per seconds), in the absence of external calcium, is of a very low intensity (lower than 100 cps) in all conditions examined. In those conditions, in fact, the calcium concentration in the cytoplasm, where the PKC β -
15 AEQ probe (in the absence of glucose) is localized, and under the plasmatic membrane, i.e. where the PKC β -AEQ probe translocates following treatment with glucose, is very low (0.1 μ M).

The addition of external calcium induces a sustained
20 flow of said ion through the channels situated on the plasmatic membrane with a consequent increase in the calcium concentration in the region under the plasmatic membrane. Under these conditions, an enormous increase in the emission of photons (> 100,000 cps) is registered
25 only in the cells expressing the PKC β -AEQ probe, treated

with high glucose, indicating the completed translocation of kinase under hyperglycaemia conditions.

The cells kept under hyperglycaemia conditions, treated with the anti-diabetic drug show a considerable
5 decrease in the response, in terms of photon emissions (lower than 40,000 cps) which means a good inhibition of the PKC β -AEQ probe translocation.

In the control cells, no significant variation is observed of the emission of photons on the part of ae-
10 quorin (lower than 10,000 cps).

From the graph, it appears evident that the treatment of cells kept under high glucose conditions by means of the anti-diabetic drug metformin, inhibits the translocation induced by glucose under hyperglycaemia condi-
15 tions.

With this system, it is not only possible to identify the molecules capable of inhibiting a translocation, but also to evaluate its efficiency, by expressing it on the basis of a range between the cps value obtained under
20 control conditions (0%) (without glucose) and that obtained following maximal translocation (100%) (after treatment with high glucose), which can be described as follows:

- GOOD inhibitor for values ranging from 10% to 40%
25 with respect to the maximal activation;

- MEDIUM inhibitor for values ranging from 40% to 70% with respect to the maximal activation;
- POOR activator for values ranging from 70% to 100% with respect to the maximal activation.

5 This result clearly shows the validity of the system proposed for measuring the translocation of proteins from the cytosol compartment to the plasmatic membrane in response to external stimulations.

EXAMPLE 3: Analysis of the translocation to the plasmatic
 10 *membrane of the protein adaptor p66 belonging to the family of shc proteins.*

MATERIALS AND METHODS

Construction of the chimeric p66shc-aequorin probe

A chimeric probe p66shc-aequorin was designed in order to further validate our procedure.

The nucleotide sequence of the protein p66shc used for the construction of the p66shc-aequorin probe has, as a reference: PUBMED 9049300.

The nucleotide sequence of aequorin used for the construction of p66shc-aequorin probes is the following:

ATG AAG CTT TAT GAT GTT CCT GAT TAT GCT AGC CTC AAA
 CTT ACA TCA GAC TTC GAC AAC CCA AGA TGG ATT GGA CGA
 CAC AAG CAT ATG TTC AAT TTC CTT GAT GTC AAC CAC AAT
 GGA AAA ATC TCT CTT GAC GAG ATG GTC TAC AAG GCA TCT
 25 GAT ATT GTC ATC AAT AAC CTT GGA GCA ACA CCT GAG CAA

GCC AAA CGA CAC AAA GAT GCT GTA GAA GCC TTC TTC GGA
GGA GCT GGA ATG AAA TAT GGT GTG GAA ACT GAT TGG CCT
GCA TAT ATT GAA GGA TGG AAA AAA TTG GCT ACT GAT GAA
TTG GAG AAA TAC GCC AAA AAC GAA CCA ACG CTC ATC CGT
5 ATA TGG GGT GAT GCT TTG TTT GAT ATC GTT GAC AAA GAT
CAA AAT GGA GCC ATT ACA CTG GAT GAA TGG AAA GCA TAC
ACC AAA GCT GCT GGT ATC ATC CAA TCA TCA GAA GAT TGC
GAG GAA ACA TTC AGA GTG TGC GAT ATT GAT GAA AGT GGA
CAA CTC GAT GTT GAT GAG ATG ACA AGA CAA CAT TTA GGA
10 TTT TGG TAC ACC ATG GAT CCT GCT TGC GAA AAG CTC TAC
GGT GGA GCT GTC CCC TAA.

This probe was obtained by inserting, in a eukaryotic expression vector (pcDNA3; 5.4 kb), the sequence encoding the p66shc protein condensed in frame with the sequence encoding aequorin.

The localization of the chimeric probe is determined by signal peptides contained inside the native sequence of the protein whose intracellular path is to be followed, in this specific case p66shc. The addition of the cDNA of aequorin to the C-terminal of the sequence encoding p66shc does not alter either the orientation or the physiological behaviour of the protein being examined.

At this point, transfection is effected of the chimeric protein probe obtained in different cellular lines, such as A431, DMS 79.

Engineering of the cellular line

In the example illustrated, it was not necessary for the cellular line used to express any other element to activate the cellular response. It is possible, however, depending on study requirements, to induce the cells to express a specific receptor for the molecule/drug to be tested in order to ensure an effective linkage degree, thus simplifying the functional analysis of the transduction systems.

10 Cellular transfection

The cells cultivated on cellular culture flasks (75 cm²) were transfected with a vector containing the chimeric probe produced, using the most suitable transfection techniques for the cellular line in question. The stabilized transfected cellular line A431 was adopted as experimental model, using the "Effectene reagent" procedure (Qiagen, Germany), which guarantees a high percentage of positive cells for this cellular line.

24 hours after the transfection, the cells were maintained in a DMEM culture medium, without serum.

Collection of cells expressing the chimeric probe

36 hours after transfection, the cells contained in the flask were detached from the bottom by trypsinization. The cellular suspension was then transferred to a Falcon tube (15 to 50 ml) and subjected to centrifugation

at 1200 rpm at 20°C and finally the cellular precipitate was re-suspended in KRB (Krebs-Ringer modified buffer: 125 mM NaCl, 5 mM KCl, 1 mM Na₃PO₄, 1 mM MgSO₄, 5.5 mM glucose, 20 mM HEPES, pH 7.4, 37°C).

5 Reconstitution of the aequorin photo-protein to active form

The prosthetic group celentherazine was added to the suspension of cells expressing the p66shc-aequorin probe, at a final concentration of 5 µM.

10 Planting on multi-well plates

50 µl of suspension containing transfected cells (corresponding to about 100,000 cells) were planted in each well of the plate. The cells were left to adhere for a time varying from 1 to 2 hours keeping them in the
15 dark, due to the photo-instability of celentherazine.

Detection of the response

At the end of the incubation period, the various molecules to be tested were added to each well and the plate with the treated cells was then put in direct con-
20 tact with a photo-multiplier which measures the emission of photons on the part of aequorin.

RESULTS

This simple test can be used for testing compounds capable of modulating the translocation of proteins of
25 the shc family in live cells.

Figures 6 shows a graphs which indicates the measuring of the translocation of p66shc, according to the method described above.

The examples shown were carried out on two parallel
5 batches of cells:

a) A431 cells expressing the p66shc-aequorin (p66shc-AEQ) probe (dark lines).

These cells were in turn subdivided into:

- A431 p66shc-aequorin cells treated with EGF (epidermic growth factor) (100 ng/ml) (thick dark line);
10
- control A431 p66shc-aequorin cells, i.e. non treated with EGF (thin dark line);

b) A431 cells expressing the cytosol aequorin probe (cyt-AEQ) (not condensed to any protein) (light
15 lines).

These cells were in turn subdivided into:

- A431 cells with cytosol aequorin treated with EGF (100 ng/mL) (thick light line);
- control A431 cells with cytosol aequorin, i.e. non
20 treated with EGF (thin light line).

As can be observed from the trend of the graphs shown in figure 6, in the absence of external calcium, the emission of photons (expressed as cps: counts per second) has a very low intensity (lower than 100 cps),
25 under all the conditions examined. Under such conditions,

in fact, the concentration of calcium in the cytoplasm, where the cyt-AEQ probes (both in the absence and in the presence of EGF growth factor) and p66shc-AEQ probes (in the absence of EGF) are located, and below the plasmatic
5 membrane, i.e. where the p66shc-AEQ probe translocates following treatment with EGF, is very low (0.1 μM).

The addition of external calcium induces a significant flow of this ion through the channels situated on the plasmatic membrane with a consequent increase in the
10 concentration of calcium in the region below the plasmatic membrane. Under these conditions, an enormous increase in the emission of photons is registered (> 100,000 cps) only in the cells expressing the p66shc-AEQ probe, treated with EGF, indicating the complete translo-
15 cation of the protein.

In all the other groups of cells, there is no significant variation in the emission of photons (lower than 10,000 cps) on the part of aequorin.

From the graph, it is evident that all the cps val-
20 ues higher than those observed in the absence of the maximal activator (EGF) will indicate a complete translocation of the kinase. With this system, it is therefore possible to identify, on the one hand, the molecules capable of inducing a translocation of the shc proteins
25 through alternative paths with respect to that activated

by the EGF growth factor, and, on the other hand, those molecules capable of blocking the intracellular transduction path activated by the EGF factor, by verifying the completed or non-completed translocation of the protein.

5 It is also possible to determine the efficiency with which a molecule induces (or blocks) said translocation by expressing it on the basis of a range between the cps value obtained under control conditions (0%) (without EGF) and that obtained following maximal translocation
10 (100%) (after treatment with EGF), which can be described as follows:

- GOOD activator for values ranging from 70% to 100% with respect to the maximal activator;
- MEDIUM activator for values ranging from 40% to 70%
15 with respect to the maximal activator;
- POOR activator for values ranging from 10% to 40% with respect to the maximal activator;
- NON-activator for values below 10% with respect to the maximal activator.

20 This result clearly shows the validity of the system proposed for measuring the translocation of proteins from the cytosol compartment to the plasmatic membrane in response to external stimulations.

EXAMPLE 4: *Analysis of the variation in concentration of
25 a second cellular messenger of interest, cAMP.*

MATERIALS AND METHODS

Construction of the mt-AEQ probe

The description of the mt-AEQ probe is described in detail in the article (Rizzuto et al., 1992).

5 Engineering of the cellular expression line of the mt-aequorin probe

For this application, two cellular lines were engineered to enable them to express two different chimeric receptors on which a different drugs capable of regulating the functions of cAMP, could be tested.

The first chimeric receptor used was constructed by condensing the extra-cellular portion of a beta adrenergic receptor (coupled with the production of cAMP) with the intra-cellular portion of an alpha adrenergic receptor (coupled with variations in the concentration of calcium) (Cotecchia et al., 1992) hereafter called beta/alpha adrenergic receptor.

Said receptor was expressed in HeLa cells thus obtaining an engineered cellular line capable of responding to stimulation with a certain drug of interest.

The second chimeric receptor used was constructed by condensing the extra-cellular portion of the ORL1 receptor for nociceptine (coupled with the production of cAMP) with the intracellular portion of an alpha adrenergic receptor (coupled with variations in the calcium concen-

tration) (Cotecchia et al., 1992) hereafter called ORL1/alpha adrenergic receptor.

Said receptor was expressed in CHO cells, thus obtaining an engineered cellular line capable of responding
5 to stimulation with a certain drug of interest.

Cellular transfection

The cellular lines thus engineered were then both transfected with the vector containing the mt-AEQ probe by means of the calcium phosphate technique.

10 Collection of the cells expressing the chimeric probe

36 hours after the transfection, the cells, cultivated on flasks for cellular cultures (75 cm²), were detached from the bottom by trypsinization. The cellular suspension was then transferred to a Falcon tube (of 15
15 or 50 ml) and subjected to centrifugation at 1200 rpm in a cell centrifuge at 20°C and finally the cellular precipitate was re-suspended in KRB/Ca²⁺ (Krebs-Ringer modified buffer: 125 mM NaCl, 5 mM KCl, 1 mM CaCl₂, 1 mM Na₃PO₄, 1 mM MgSO₄, 5.5 mM glucose, 20 mM HEPES, pH 7.4,
20 37°C).

Reconstitution of the aequorin photo-protein to active form

The prosthetic group celentherazine was added at a final concentration of 5 µM to the suspension of engineered cells expressing the mt-AEQ probe.
25

Planting on multi-well plates

50 μ l of suspension containing transfected cells (corresponding to about 100,000 cells) were planted in each well of the plate. The cells were left to adhere for a time varying from 1 to 2 hours keeping them in the dark, due to the photo-instability of celentherazine.

Detection of the response

At the end of the incubation time, the various molecules to be tested were added to each well and the plate with the treated cells was then put in direct contact with a photo-multiplier which measures the emission of photons on the part of aequorin.

RESULTS

This simple test can therefore be used for testing compounds capable of inducing, by the activation of specific receptors, variations in the concentration of cAMP.

The experiment was carried out on HeLa and CHO cells expressing the mt-AEQ probe and the chimeric receptor (beta/alpha adrenergic) and the chimeric receptor (ORL1/alpha adrenergic), respectively.

The HeLa cells (figure 7) were treated with:

- Histamine (100 μ M, SIGMA) to induce the normal increase in calcium due to the stimulation of the endogenous receptor for histamine H1 (dark line).
- Isoproterenol (100 μ M, SIGMA) to induce an increase in

calcium due to the stimulation of the chimeric receptor (light line).

HeLa cells expressing a beta adrenergic receptor and stimulated with isoproterenol for inducing the stimulation of said receptor, were used as control (dotted line).

The CHO cells (figure 8) were treated with:

- ATP (100 μ M, SIGMA) to induce the normal increase in calcium due to the stimulation of the endogenous receptor for ATP P2Y (dark line).

- Nociceptine (1 μ M) to induce an increase in calcium due to the stimulation of the chimeric receptor (light line).

CHO cells expressing a wild-type ORL1 receptor and stimulated with nociceptine for inducing the stimulation of said receptor, were used as control (dotted line).

Figures 7 and 8 show the graphs which indicate two examples of the measurement of the production and variation in concentration of cAMP with the method described above. As can be observed from an analysis of the graphs, in the absence of stimulation, the emission of photons (cps: counts per second) is very low, almost null (100 cps). Under these basic conditions, the concentration of calcium in the mitochondrial matrix where the mt-AEQ probes are located, is extremely low (0.2 μ M).

Stimulation with histamine, in the case of the HeLa cells, and with ATP, in the case of the CHO cells, induces a considerable and transient increase in the concentration of calcium in the mitochondrial matrix as widely described in literature (Rizzuto et al., 1992; Pinton et al., 1998).

This increase is reflected in an enormous emission of photons on the part of aequorin (from less than 20 photons emitted per second to over 80,000 photons).

10 In order to verify the validity of the system proposed, we stimulated the cells with a specific agonist of the extra-cellular portion of the chimeric receptor (isoproterenol and nociceptine). The light line shows how, also in this case, there is a significant increase in the
15 emission of photons on the part of aequorin (from less than 20 photons emitted per second to over 80,000 photons) indicating that stimulation with isoproterenol and nociceptine (normally coupled with the production and increase in the concentration of cAMP) is converted into a
20 signal linked to the variation in the concentration of calcium. On the contrary, the stimulation with isoproterenol of cells expressing a beta adrenergic receptor and the stimulation with nociceptine of cells expressing an ORL1 wild-type receptor, coupled therefore with the
25 production of cAMP, does not induce any increase in cps, in-

dicating the non-increase in concentration of calcium. It is evident that any substance which induces an increase in cps in cells expressing a chimeric receptor having the intracellular portion coupled with variations in the concentration of calcium, will be capable of modifying the concentration of cAMP.

This result clearly demonstrates the validity of the system proposed for measuring the activation of specific receptors coupled with the production of cAMP.

10 EXAMPLE 5: Analysis of the activation/inhibition of the catalytic activity of a cellular effector of interest, PKC, in controlling the functional state of channels for calcium.

In order to validate this method, analysis experiments were effected, of the catalytic activity of PKC on specific calcium channels situated at the level of the plasmatic membrane called L-type Ca²⁺ channels.

In this specific case, the cells were transfected with a Ca²⁺ channel of the L type, inhibited by a PKC-dependent phosphorylation, and with a probe represented by an aequorin localized below the plasmatic membrane (SNAP-AEQ) (Marsault et al., 1997), in direct contact with the channel being examined.

MATERIALS AND METHODS

Construction of the SNAP-AEQ probe

The description of the SNAP-AEQ probe is described in detail in the article (Marsault et al., 1997).

Engineering of the cellular expression line of the SNAP-

5 AEQ probe

For this application, it is necessary to engineer a cellular line with the calcium channel (in this case of the L type).

The HeLa cells were engineered so as to express the
10 calcium channel whose activity is regulated by the cellular effector of interest (PKC).

Cellular transfection

The engineered cellular line was then transfected with the vector containing the SNAP-AEQ probe by means of
15 the calcium phosphate method.

Collection of the cells expressing the chimeric probe

36 hours after the transfection, the cells, cultivated on flasks for cellular cultures (75 cm²), were detached from the bottom by trypsinization. The cellular
20 suspension was then transferred to a Falcon tube (of 15 or 50 ml) and subjected to centrifugation at 1200 rpm, in a cell centrifuge at 20°C and finally the cellular precipitate was re-suspended in KRB (Krebs-Ringer modified buffer: 125 mM NaCl, 5 mM KCl, 1 mM Na₃PO₄, 1 mM MgSO₄,
25 5.5 mM glucose, 20 mM HEPES, pH 7.4, 37°C).

Reconstitution of the aequorin photo-protein to active form

The prosthetic group celentherazine was added at a final concentration of 5 μ M to the suspensions of engineered cells expressing the SNAP-AEQ probe.

Planting on multi-well plates

50 μ l of suspension containing the transfected and reconstituted cells (corresponding to about 100,000 cells) were planted in each well of the plate. The cells were left to adhere for a time varying from 1 to 2 hours keeping them in the dark, due to the photo-instability of celentherazine.

Detection of the response

At the end of the incubation time, the various molecules to be tested were added to each well and the plate with the treated cells was then put in direct contact with a photo-multiplier which measures the emission of photons on the part of aequorin.

With this test it is possible to identify the molecules capable of modifying the catalytic activity of cellular effectors of interest and consequently the functional state of the calcium channels.

BIBLIOGRAPHY

- Brini,M., M. Murgia, L.Pasti, D.Picard, T.Pozzan,
and R.Rizzuto. 1993. *EMBO J.* 12:4813-4819.
- Brini,M., R.Marsault, C.Bastianutto, T.Pozzan, and
5 R.Rizzuto. 1994a. *Cell Calcium* 16:259-268.
- Brini,M., L.Pasti, C.Bastianutto, M.Murgia,
T.Pozzan, and R.Rizzuto. 1994b. *J. Biolumin. Chemilumin.*
9:177-184.
- Brini,M., R.Marsault, C.Bastianutto, J.Alvarez,
10 T.Pozzan, and R.Rizzuto. 1995. *J. Biol. Chem.* 270:9896-
9903.
- Brini,M., F.De Giorgi, M.Murgia, R.Marsault,
M.L.Massimino, M.Cantini, R.Rizzuto and T.Pozzan. 1997.
Mol. Biol. Cell 8:129-143.
- 15 - Brini,M., P.Pinton, T.Pozzan, and R.Rizzuto. 1999.
Microsc.Res.Tech. 46:380-389.
- Chiesa,A., E.Rapizzi, V.Tosello, P.Pinton, M.de Vir-
gilio, K.E.Fogarty, and R.Rizzuto. 2001. *Biochem. J.*
355:1-12.
- 20 - Cotecchia,S., F.Ostrowski, M.A.Kjelsberg, M.G.Caron,
and R.J.Lefkowitz. 1992. *J. Biol. Chem.* 267:1633-1639.
- De Giorgi,F., M.Brini, C.Bastianutto, R.Marsault,
M.Montero, P.Pizzo, and R.Rizzuto. 1996. *Gene* 173:113-
117.
- 25 - Grynkiewicz.G., M.Poenie, and R.Y.Tsien. 1985. *J.*

- Biol. Chem.* 260:3440-3450.
- Marsault, R. M. Murgia, T. Pozzan, and R. Rizzuto. 1997. *EMBO J.* 16:1575-1581.
 - Montero, M., M. Brini, R. Marsault, J. Alvarez, R. Sitia,
5 T. Pozzan, and R. Rizzuto. 1995. *EMBO J.* 14:5467-5475.
 - Pinton, P., M. Brini, C. Bastianutto, R. A. Tuft,
T. Pozzan, and R. Rizzuto. 1998. *Biofactors* 8:243-253.
 - Pinton, P., T. Pozzan, and R. Rizzuto. 1998. *EMBO J.*
17:5298-5308.
 - 10 - Porcelli, A. M., P. Pinton, E. K. Ainscow, A. Chiesa,
M. Rugolo, G. A. Rutter, and R. Rizzuto. 2001. *Methods Cell
Biol.* 65:353-380.
 - Ridgway, E. B. and C. C. Ashley. 1967. *Biochem. Biophys.
Res. Commun.* 29:229-234.
 - 15 - Rizzuto, R., A. W. Simpson, M. Brini, and T. Pozzan.
1992. *Nature* 358:325-327.
 - Rizzuto, R., M. Brini, and T. Pozzan. 1993. *Cytotech-
nology* 11 Suppl 1:S44-S46.
 - Rizzuto, R., M. Brini, and T. Pozzan. 1994. *Methods*
20 *Cell Biol.* 40:339-358.
 - Rizzuto, R., M. Brini, C. Bastianutto, R. Marsault, and
T. Pozzan. 1995. *Methods Enzymol.* 260:417-428.
 - Rizzuto, R., P. Pinton, W. Carrington, F. S. Fay,
K. E. Fogarty, L. M. Lifshitz, R. A. Tuft, and T. Pozzan. 1998.
25 *Science* 280:1763-1766.

- Robert, V., P. Pinton, V. Tosello, R. Rizzuto, and T. Pozzan. 2000. *Methods Enzymol.* 327:440-456.
- Rutter, G.A., P. Burnett, R. Rizzuto, M. Brini, M. Murgia, T. Pozzan, J.M. Tavare, and R.M. Denton. 1996. *Proc. Natl. Acad. Sci. U.S.A.* 93:5489-5494.
- 5 - Shimomura, O., F.H. JOHNSON, and Y. SAIGA. 1962. *J. Cell Comp Physiol* 59:223-239.
- Tsien, R.Y., T. Pozzan, and T.J. Rink. 1982. *Nature* 295:68-71.
- 10 - Zhang, J., R.E. Campbell, A.Y. Ting, and R.Y. Tsien. 2002. *Nat. Rev. Mol. Cell Biol.* 3:906-918

15

20

25

CLAIMS

1. A screening method of molecules capable of generating the alteration of a target intracellular parameter, said alteration being converted into a proportional variation in the intracellular concentration of the Ca^{2+} ion, detected by means of a Ca^{2+} -sensitive recombinant protein probe, comprising the following phases:
- a) construction of an expression vector containing the sequence encoding said probe, said sequence being characterized in that it comprises sequences encoding at least one Ca^{2+} -sensitive photo-protein, and at least one cellular effector or a signal sequence, condensed together;
 - b) transfection of at least one cellular line of a mammal with said vector containing the Ca^{2+} -sensitive recombinant protein probe;
 - c) activation of said Ca^{2+} -sensitive photo-protein by the addition of a prosthetic group to the cellular line expressing said recombinant protein probe;
 - d) administration of the molecule to be tested to the cellular line expressing said recombinant protein probe;
 - e) detection of the emission of photons on the part of the Ca^{2+} -sensitive photo-protein expressed in the cellular line and evaluate the amount of activation or inhibition exerted by the tested molecule, on the basis of a ratio between the cps value obtained and the maximum

value of cps registered under conditions of maximum stimulation of the cellular line.

2. The method according to claim 1, wherein said Ca^{2+} -sensitive photo-protein is aequorin.

5 3. The method according to claim 1 and 2, wherein said prosthetic group is celentherazine.

4. The method according to claims 1 to 3, wherein said alteration of an intracellular parameter is selected from the group which comprises variation in the concentration
10 of a second messenger, translocation to the membrane or activation/inactivation state of a cellular effector.

5. The method according to claim 4, wherein said second messenger is selected from the group which comprises cyclic nucleotides, adenosine nucleotides, diacylglycerol,
15 Ca^{2+} and inositol 1,4,5-triphosphate.

6. The method according to claim 4, wherein said cellular effector is selected from the group which consists of ionic channel, regulating protein, cellular membrane receptor.

20 7. The method according to claim 6, wherein said ionic channel is selected from the group which comprises voltage dependent Ca^{2+} channels and Ca^{2+} channel-receptors.

8. The method according to claim 6, wherein said regulating protein is selected from the group which comprises
25 protein-kinase, phosphatase, adenylate cyclase, proteins

that link plasmatic membrane receptors, proteins that interact with plasmatic membrane channels, proteins that interact with plasmatic membrane lipids.

9. The method according to claim 6, wherein said cellular membrane receptor is selected from the group which comprises receptors coupled with G proteins, receptors with an enzymatic activity, channel receptors.

10. The method according to any of the previous claims, wherein said Ca^{2+} -sensitive recombinant protein probe is characterized in that it comprises the amino acidic sequence of at least one Ca^{2+} -sensitive photo-protein, or parts thereof.

11. The method according to claim 10, wherein the protein probe additionally comprises a signal sequence and/or the amino acidic sequence of a cellular effector.

12. The method according to claim 11, wherein said cellular effector is selected from the group which consists of ionic channel, regulating protein, cellular membrane receptor.

13. The method according to claim 12, wherein said ionic channel is selected from the group which comprises voltage-dependent Ca^{2+} channels and Ca^{2+} channel receptors.

14. The method according to claim 12, wherein said regulating protein is selected from the group which comprises protein-kinase, phosphatase, adenylate cyclase, proteins

that link plasmatic membrane receptors, proteins that interact with plasmatic membrane channels, proteins that interact with plasmatic membrane lipids.

15. The method according to claim 14, wherein said protein-kinase are protein-kinase C (PKC).

16. The method according to claim 12, wherein said cellular membrane receptor is selected from the group which comprises receptors coupled with G proteins, receptors with an enzymatic activity, channel receptors.

10 17. The method according to claims 10 and 11, wherein said signal sequence directs the Ca²⁺-sensitive photoprotein, preferably aequorin, to a cellular compartment.

18. The method according to any of the claims from 10 to 17, wherein the protein probe is a condensation protein
15 selected from the group which consists of PKC-aequorin (PKC-AEQ), shc-aequorin (shc-AEQ), SNAP-aequorin (SNAP-AEQ), mt-aequorin (mt-AEQ), cytosol aequorin (cyt-AEQ).

19. The method according to claim 18, wherein the PKC-aequorin is selected from the group which comprises PKC
20 beta-aequorin, PKC delta-aequorin, PKC epsilon-aequorin, PKC zeta-aequorin, PKC gamma-aequorin, PKC alpha-aequorin, PKC-lambda-aequorin, PKC theta-aequorin, PKC eta-aequorin.

20. The method according to claim 18, wherein the shc-aequorin is selected from the group consisting of p66shc-
25

aequorin, p46shc-aequorin, p52shc-aequorin.

21. The method according to claim 1, wherein the expression vector of phase a) is a eukaryotic vector.

22. The method according to claim 1, wherein said at
5 least one mammal cellular line is previously engineered so as to express a heterologic native or chimeric protein.

23. The method according to claim 22, wherein said heterologic protein is selected from the group which consists of a receptor, an enzyme, an ionic channel or a
10 cellular effector.

24. The method according to claim 23, wherein said receptor is a chimeric receptor.

25. The method according to claim 24, wherein said chimeric receptor is characterized in that it has the intracellular portion of a receptor coupled with variations in
15 the concentration of calcium and the extra-cellular portion of a receptor coupled with the production of cAMP.

26. The method according to claim 23, wherein said ionic
20 channel is selected from the group which comprises voltage-dependent Ca^{2+} channels and Ca^{2+} channel receptors.

27. The method according to claim 23, wherein said cellular effector is selected from the group which consists of ionic channel, regulating protein, cellular membrane
25 receptor.

28. The method according to claim 27, wherein said ionic channel is selected from the group which comprises voltage-dependent Ca^{2+} channels and Ca^{2+} channel receptors.

29. The method according to claim 27, wherein said regulation protein is selected from the group which comprises
5 protein-kinase, phosphatase, adenylate cyclase, proteins that link plasmatic membrane receptors, proteins that interact with plasmatic membrane channels, proteins that interact with plasmatic membrane lipids.

10 30. The method according to claim 27, wherein said cellular membrane receptor is selected from the group which comprises receptors coupled with G proteins, receptors with an enzymatic activity, channel receptors.

15 31. A Ca^{2+} -sensitive recombinant protein probe, characterized in that it comprises amino acidic sequences of at least one Ca^{2+} -sensitive photo-protein, or parts thereof, and a cellular effector or a signal sequence, condensed together.

20 32. The probe according to claim 31, wherein said Ca^{2+} -sensitive photo-protein is aequorin.

33. The probe according to claims 31 and 32, wherein said protein probe additionally comprises a signal sequence and/or the amino acidic sequence of a cellular effector.

25 34. The probe according to claims 31 to 33, wherein said

cellular effector is selected from the group which consists of ionic channel, regulating protein, cellular membrane receptor.

35. The probe according to claim 34, wherein said ionic
5 channel is selected from the group which comprises voltage-dependent Ca^{2+} channels and Ca^{2+} channel receptors.

36. The probe according to claim 34, wherein said regulating protein is selected from the group which comprises protein-kinase, phosphatase, adenylate cyclase, proteins
10 that link plasmatic membrane receptors, proteins that interact with plasmatic membrane channels, proteins that interact with plasmatic membrane lipids.

37. The probe according to claim 36, wherein said protein-kinase are protein kinase C (PKC).

15 38. The probe according to any of the claims from 31 to 37, wherein said probe is a condensation protein which consists of PKC-aequorin (PKC-AEQ).

39. The probe according to claim 38, wherein the PKC-aequorin is selected from the group which comprises PKC
20 beta-aequorin (PCK beta: rif. M13975), PKC delta-aequorin (PCK delta: rif. M18330), PKC epsilon-aequorin (PCK epsilon: rif. AF028009), PKC zeta-aequorin (PCK zeta: rif. M18332), PKC gamma-aequorin, PKC alpha-aequorin (PCK alfa: rif. M13973), PKC-lambda-aequorin, PKC theta-
25 aequorin (PCK theta: rif. L07032), PKC eta-aequorin.

40. The probe according to claim 36, wherein said proteins which link plasmatic membrane receptors belong to the shc family.
41. The probe according to claim 40, wherein the protein
5 is selected from the group comprising p46shc, p52shc and p66shc.
42. The probe according to claim 34, wherein said cellular membrane receptor is selected from the group which comprises receptors coupled with G proteins, receptors
10 with an enzymatic activity, channel receptors.
43. The probe according to claims 31 to 42, wherein said signal sequence directs the Ca²⁺-sensitive photo-protein, preferably aequorin, towards a cellular compartment.
44. Use of the Ca²⁺-sensitive recombinant probe as de-
15 fined in claims 31 to 42, for the screening of molecules capable of generating the alteration of an intracellular parameter, said alteration being converted into a proportional variation in the intracellular concentration of the Ca²⁺ ion.
- 20 45. Use according to claim 44, wherein said alteration of an intracellular parameter is selected from the group which comprises variation in concentration of a second messenger, translocation to the membrane or activation/inactivation state of a cellular effector.
- 25 46. Use according to claim 45, wherein said second mes-

senger is selected from the group which comprises cyclic nucleotides, nucleotides of adenosine, diacyl glycerol, Ca²⁺ and inositol 1,4,5 triphosphate.

47. Use according to claim 45, wherein said cellular ef-
5 factor is selected from the group which consists of ionic channel, regulating protein, cellular membrane receptor.

48. Use according to claim 47, wherein said ionic chan-
nel is selected from the group which comprises voltage-
dependent Ca²⁺ channels and Ca²⁺ channel receptors.

10 49. Use according to claim 47, wherein said regulation
protein is selected from the group which comprises pro-
tein-kinase, phosphatase, adenylate cyclase, proteins
that link plasmatic membrane receptors, proteins that in-
teract with plasmatic membrane channels, proteins that
15 interact with plasmatic membrane lipids.

50. Use according to claim 47, wherein said cellular
membrane receptor is selected from the group which com-
prises receptors coupled with G proteins, receptors with
an enzymatic activity, channel receptors.

20

25




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8